BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a research report on Wednesday, November 6th.

BioLineRx Stock Down 2.3 %

Shares of NASDAQ:BLRX opened at $0.27 on Friday. The business has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.61. BioLineRx has a 12-month low of $0.25 and a 12-month high of $1.89. The company has a current ratio of 1.61, a quick ratio of 1.49 and a debt-to-equity ratio of 1.34. The company has a market capitalization of $21.72 million, a price-to-earnings ratio of -0.60 and a beta of 1.48.

Institutional Investors Weigh In On BioLineRx

Hedge funds and other institutional investors have recently made changes to their positions in the business. CVI Holdings LLC acquired a new position in BioLineRx in the second quarter valued at approximately $462,000. PVG Asset Management Corp purchased a new stake in shares of BioLineRx during the 2nd quarter worth approximately $70,000. Finally, Atria Investments Inc lifted its position in shares of BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.